Medtronic Confident Renal Denervation Trial Will Work This Time
Executive Summary
US FDA has approved Medtronic's plan for the SPYRAL HTN Pivotal Trial, part of the SPYRAL HTN Global Clinical Program. SPYRAL HTN is a multi-phased clinical study strategy to establish the safety and efficacy of renal denervation with the Symplicity Spyral system to reduce blood pressure in patients with uncontrolled hypertension. The Spyral device and procedure, as well as the design of the SPYRAL HTN clinical trial, reflect lessons learned from SYMPLICITY HTN-3, the first sham-controlled trial of renal denervation, which famously failed to show a benefit of the procedure.